Baird Initiates Coverage On Elevance Health with Outperform Rating, Announces Price Target of $649
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Michael Ha has initiated coverage on Elevance Health (NYSE:ELV) with an Outperform rating and set a price target of $649.
May 30, 2024 | 9:56 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Baird analyst Michael Ha has initiated coverage on Elevance Health with an Outperform rating and a price target of $649.
The initiation of coverage with an Outperform rating and a high price target of $649 by a reputable analyst is likely to positively impact Elevance Health's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100